

Paul Beninger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6245042/publications.pdf>

Version: 2024-02-01

21
papers

188
citations

1478280

6
h-index

1125617

13
g-index

21
all docs

21
docs citations

21
times ranked

177
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacovigilance: An Overview. <i>Clinical Therapeutics</i> , 2018, 40, 1991-2004.	1.1	63
2	Pharmacovigilance and Biomedical Informatics: A Model for Future Development. <i>Clinical Therapeutics</i> , 2016, 38, 2514-2525.	1.1	40
3	COVID-19: Regulatory Landscape of Medicinal and Medical Device Products for Human Use. <i>Clinical Therapeutics</i> , 2020, 42, 1444-1450.	1.1	15
4	Opportunities for Collaboration at the Interface of Pharmacovigilance and Manufacturing. <i>Clinical Therapeutics</i> , 2017, 39, 702-712.	1.1	12
5	Who has not been vaccinated, fully vaccinated, or boosted for COVID-19?. <i>American Journal of Infection Control</i> , 2022, 50, 1185-1189.	1.1	12
6	The Application of Engineering Principles and Practices to Medical Education: Preparing the Next Generation of Physicians. <i>Medical Science Educator</i> , 2021, 31, 897-904.	0.7	9
7	Signal Management in Pharmacovigilance: A Review of Activities and Case Studies. <i>Clinical Therapeutics</i> , 2020, 42, 1110-1129.	1.1	5
8	Influence of COVID-19 on the Pharmacovigilance Workforce of the Future. <i>Clinical Therapeutics</i> , 2021, 43, 369-371.	1.1	5
9	Pharmacovigilance: Work in Progress. <i>Pharmaceutical Medicine</i> , 2017, 31, 1-5.	1.0	4
10	Data Sharing in the Pharmaceutical Enterprise: The Genie's Out of the Bottle. <i>Clinical Therapeutics</i> , 2017, 39, 1890-1894.	1.1	4
11	Pharmacovigilance: Challenges in Getting From Here to There. <i>Clinical Therapeutics</i> , 2018, 40, 1964-1966.	1.1	4
12	Entrepreneurship for a meaningful clinical experience. <i>BMJ Innovations</i> , 2019, 5, 1-7.	1.0	4
13	Review of FDA Amendments Act Section 921 Experience in Posting Data-mining Results from the FAERS Database. <i>Clinical Therapeutics</i> , 2021, 43, 380-395.	1.1	4
14	Risk Communication in a Pharmacovigilance Environment. <i>Clinical Therapeutics</i> , 2017, 39, 672-674.	1.1	2
15	Bridging the Academia/Industry Chasm: Proposed Solutions. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 1457-1460.	1.0	1
16	Pharmacovigilance in the New Millennium. <i>Clinical Therapeutics</i> , 2016, 38, 2512-2513.	1.1	1
17	Theranos Experience Exposes Weaknesses in FDA Regulatory Discretion. <i>Clinical Pharmacology in Drug Development</i> , 2017, 6, 433-438.	0.8	1
18	Mind the gap: COVID-19 highlights the research void in pregnancy. <i>American Journal of Obstetrics & Gynecology MFM</i> , 2022, 4, 100566.	1.3	1

#	ARTICLE	IF	CITATIONS
19	Need for a contingency dimension when planning vaccine development in a pandemic environment. <i>Vaccine</i> , 2022, 40, 2895-2896.	1.7	1
20	Medical Schoolsâ€™ Competition for Clinical Training Sites. <i>Academic Medicine</i> , 2016, 91, 1588-1588.	0.8	0
21	Dynamic Dossier in the Cloud: A Sociotechnical Architecture for a Real-Time and Metrics-Based Data Tracking System with Gene and Cell Therapies as a Case Study. <i>Therapeutic Innovation and Regulatory Science</i> , 2021, 55, 388-400.	0.8	0